logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

Rezolute, Inc.

RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developā€¦ read more

Healthcare

Biotechnology

13 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$4.66

Price

-1.27%

-$0.06

$4.72

Previous Close

$4.68

Open

Premium

52w Discount
Market Cap

$448.722m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$81.485m

-9.5%

1y CAGR

-16.8%

3y CAGR

-19.1%

5y CAGR
EPS

-$0.82

+16.3%

1y CAGR

+3.7%

3y CAGR

+16.9%

5y CAGR
Book Value

$116.834m

$125.459m

Assets

$8.625m

Liabilities

$1.111m

Debt
Debt to Assets

0.9%

-

Debt to EBITDA
Free Cash Flow

-$73.484m

-6.4%

1y CAGR

-18.4%

3y CAGR

-17.0%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.